A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma
NCT05481437
Summary
This study is a survey in Japan of Brentuximab Vedotin used to treat children or teenagers with Hodgkin lymphoma (HL). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related from Brentuximab Vedotin especially myelosupression, peripheral neuropathy, and lung disorder. During the study, pediatric participants with HL will take Brentuximab Vedotin injection and AVD treatment (doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine) according to their clinic's standard practice. The study doctors will check for side effects from Brentuximab Vedotin for 26 weeks.
Eligibility
Inclusion Criteria: 1. Treatment-naive participants 2. CD30 positive participants 3. Participants treated with the study drug in combination with doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine (AVD). 4. Participants aged \< 18 years at the start of this drug. Exclusion Criteria: Participants with contraindications to the study drug.
Conditions2
Interventions1
Related trials
- A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India — Takeda
- Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma — Canadian Cancer Trials Group
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab — National Cancer Institute (NCI)
- Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma — New York Medical College
- Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides — University of Alabama at Birmingham
- Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma — Joseph Tuscano
- Brentuximab Vedotin in Early Stage Hodgkin Lymphoma — University College, London
- Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients — Memorial Sloan Kettering Cancer Center
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT05481437